Gilead's GS-5829 flops in mCRPC

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Gilead's GS-5829 flops in mCRPC

posted on Jul 13, 2022 11:03AM

https://pubmed.ncbi.nlm.nih.gov/35816286/

"Conclusions: GS-5829 was generally tolerated but demonstrated limited efficacy and lack of dose-proportional increases in plasma concentrations in patients with mCRPC."

The lead PI Rahul Aggarwal on this one is the same as the one for the Zenith mCRPC trial. Bad for Gilead, great for Zenith!